Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer’s disease psychosis
Acadia Pharmaceuticals Inc.
ACAD,
said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis. The FDA’s Psychopharmacologic Drugs Advisory Committee will review Acadia’s Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer’s disease, according to the Alzheimer’s Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500
SPX,
has fallen 23%.
